Efficacy,safety and outcomes of transcatheter arterial embolization with N-butyl cyanoacrylate glue for non-variceal gastrointestinal bleeding: A systematic review and meta-analysis

PurposeTo perform a systematic review and meta-analysis to determine the safety, efficacy, and outcomes of transcatheter arterial embolization (TAE) with N-butyl cyanoacrylate (NBCA) as the single embolic agent for the management of non-variceal upper and lower gastrointestinal bleeding (GIB).Materials and methodsA literature search using MEDLINE/PubMed, EMBASE, and SCOPUS databases was performed for studies published from January 1980 to December 2019. Data from eligible studies were extracted and evaluated by two independent reviewers. Exclusion criteria were sample size < 5, article reporting the use of NBCA with other embolic agents, no extractable data, and duplicate reports. Technical success, clinical success, 30-day rebleeding, 30-day overall and major complications, and 30-day mortality were evaluated. The estimated overall rates were calculated with their 95% confidence intervals, based on each study rate, weighted by the number of patients involved in each study. Heterogeneity across studies was assessed using the Q test and I² statistic.ResultsFifteen studies with 574 patients were included. For upper GIB (331 patients), the technical and clinical success rates, and 30-day rebleeding and mortality rates, were 98.8% (328 of 331 patients) and 88.0% (237 of 300 patients), and 12.5% (69 of 314 patients) and 15.9% (68 of 331 patients), respectively. Thirty-day overall and major complications occurred in 14.3% (28 of 331 patients) and 2.7% (7 of 331 patients) of patients, respectively. For lower GIB (243 patients), the technical and clinical success rates, and 30-day rebleeding and mortality rates, were 98.8% (78 of 78 patients) and 78.0% (145 of 189 patients), and 15.7% (33 of 218 patients) and 12.7% (14 of 78 patients), respectively. Thirty-day overall and major complications occurred in 13.0% (25 of 228 patients) and 8.6% (19 of 228 patients) of patients, respectively.ConclusionTAE with NBCA is safe and effective for treating non-variceal GIB, with high clinical success and very low major complication rates.     

临床模型预测经导管动脉栓塞治疗急性非静脉曲张性上消化道出血术后30天内再出血

目的 根据急性非静脉曲张性上消化道出血（ANVUGIB）患者临床资料建立logistic模型,观察其预测经导管动脉栓塞（TAE）治疗后30天内再出血的价值。方法 纳入139例接受TAE的ANVUGIB患者,记录TAE成功率及术后30天内再出血率;基于临床资料行单因素及多因素分析,筛选再出血的影响因素,建立临床logistic模型,分析其预测TAE后再出血的价值。结果 TAE技术成功率为95.68%（133/139）。对133例TAE技术成功患者随访30天,其中29例再出血,再出血率21.80%（29/133）。术前凝血功能障碍（OR=3.74,P=0.045）及术前高Rockall评分（OR=1.97,P=0.005）为TAE治疗ANVUGIB后30天内再出血的危险因素,男性（OR=0.19,P=0.007）及术前CT阳性（OR=0.06,P=0.047）为其保护因素。基于上述4个因素建立的logistic模型预测ANVUGIB患者TAE后30天内再出血的敏感度和特异度分别为82.80%和75.00%,曲线下面积为0.817,高于Rockall评分、Blatchford评分及澳洲医药科学家协会65评分（P均<0.05）。结论 基于性别、术前凝血功能障碍情况、Rockall评分及CT表现建立的临床模型有助于预测TAE治疗ANVUGIB后30天内再出血。     

Transcatheter embolization as the new reference standard for endoscopically unmanageable upper gastrointestinal bleeding

Acute nonvariceal upper gastrointestinal bleeding(UGIB) is a major medical emergency problem associated with significant morbidity and mortality.Endoscopy is considered the first method of choice to detect and treat UGIB.Endoscopic therapy usually achieves primary hemostasis,but 10%-30% of these patients have repeat bleeding.In patients in whom hemostasis is not achieved with endoscopic techniques,treatment with transcatheter angiographic embolization(TAE) or surgery is needed.Surgical intervention is usually an expeditious and gratifying endeavor,but it can be associated with high operative mortality rates.A large number of studies support the use of TAE as salvage therapy as an alternative to surgery.However,few studies have compared the results of TAE with that of emergency surgery in terms of efficiency,the frequency of repeat bleeding,and complications.Recently,Ang et al retrospectively compared the outcome of TAE and surgery as salvage therapy of UGIB after failed endoscopic treatment.There were no significant differences in 30 d mortality,complication rates and length of stay although higher rebleeding rates were observed after TAE compared with surgery.In this commentary,we discuss the advantages and drawbacks of these two therapeutic strategies for UGIB.We also attempt to define the exact role of TAE for acute nonvariceal UGIB.     

Will transcatheter embolotherapy replace surgery in the treatment of gastrointestinal bleeding?(2)(2)

Superselective angiography and transcatheter embolization (SATE) have produced mixed results in the treatment of upper gastrointestinal bleeding (UGIB). The use of SATE to treat hemorrhage distal to the ligament of Treitz has been approached with trepidation because of limited collateral blood supply to the gastrointestinal tract beyond the duodenum. Ischemic bowel injury rates of 15% to 35% are reported when SATE is used to treat lower gastrointestinal bleeding (LGIB). Recent improvements in coaxial catheter design and embolic agents and greater expertise of personnel performing interventional angiographic procedures have decreased the risks of SATE in the lower gastrointestinal tract. The purpose of this study is to review our experience with SATE in the management of both UGIB and LGIB. %METHODS:This is a retrospective cohort study of patients undergoing SATE between January 1996 and November 1998. All SATE was performed in an angiographic suite with the latest generation coaxial catheters and embolic agents. Patient characteristics and outcome measures were noted. Efficacy of SATE was determined by analyzing the following outcome measures: initial technical success, rebleeding rate at less than 30 days post-SATE, the total rebleeding rate post-SATE, the number of patients requiring surgery despite SATE, and the complication rate. Patients undergoing SATE for LGIB were clinically monitored for development of ischemic complications.Of 523 admissions for UGIB and LGIB, 35 patients (6.7%) underwent SATE as definitive therapy for control of gastrointestinal hemorrhage (25 UGIB and 10 LGIB). Mean age of treated patients was 67 years; 49% had greater than 3 significant systemic comorbidities. Initial control of bleeding was achieved in 23/25 UGIB and 10/10 LGIB patients. Rebleeding at less than 30 days occurred in 5/23 UGIB and 2/10 LGIB patients. Rebleeding at greater than 30 days occurred in 2 additional UGIB patients. No known duodenal stenosis or ischemic bowel injury occurred in patients undergoing SATE for UGIB or LGIB, respectively, during the follow-up period.SATE is an excellent therapeutic method for GI bleeding in selected patients, and definitive control is frequently afforded. In the remainder, SATE may allow temporary control and resuscitation of the unstable patient. SATE appears to be as safe and effective for LGIB as it is for UGIB. Further studies are needed to better define the role of SATE for GI bleeding.     

����������Ѫ�������Ʋ���

??Surgical strategies for upper gastrointestinal bleeding CHEN Lin, CHEN Shao-quan. Department of General Surgery, General Hospital of Chinese PLA, Beijing 100853, China
Corresponding author: CHEN Lin, E-mail??chenlinbj@vip.sina.com
Abstract Upper gastrointestinal bleeding (UGIB) represents a common and challenging emergency. The causes of UGIB have been classified into variceal bleeding (esophageal and gastric varices) and non-variceal bleeding (peptic ulcer, erosive gastroduodenitis, reflux esophagitis, tumor, etc). Because considerable advances have been made in both endoscopic and pharmacologic therapy, UGIB is normally treated conservatively at present. However, some patients required surgical treatment when it was impossible to achieve hemostasis by pharmacotherapy and endoscopy or if rebleeding occurred where the conservative treatment had failed. According to the causes and sources of UGIB, a surgeon should be informed about the possible need for surgery and make a decision to operate. Surgery is a treatment method of important position in multidisciplinary treatment for UGIB.     

近段胃壁内外双重断流术治疗门静脉高压症出血的远期疗效

目的分析近段胃壁内外双重断流术式治疗门静脉高压症致上消化道出血的远期疗效。方法 1989—2008年笔者对住院治疗的367例肝硬化门静脉高压症致上消化道出血患者行壁内外双重断流术,择期手术309例,急诊手术58例;随访1~19年,平均随访16年。结果急诊手术止血率100%,术中断流后门静脉压力平均下降4.3 cm H2O,术后6~19年再出血共8例,再出血率2.5%。存活率1~5年,6~10年,11~19年分别为83.05%,91.85%,92.80%。结论近段胃壁内外双重断流术式治疗门静脉高压症致上消化道出血即时止血率高、并发症少、再出血率低、长期生存率高,是治疗门静脉高压症致上消化道出血安全、有效的重要手术方法。     

Upper gastrointestinal bleeding - Review of our ten years results]

Acute upper gastrointestinal bleeding (UGIB) is a common reason for emergency hospitalisation. Early upper gastrointestinal endoscopy is the corner stone of management; the alternative option for achieving primary hemostasis is emergency surgery. The aim of this study was to analyse the frequency of UGIB in the last 10 years and to present our surgical results. We observed 5 955 bleeding patients (68.4 % male and 31.6 % female) with a mean age of 57.7 inverted question mark 15.8 years. The most frequent causes of bleeding were gastric and duodenal ulcers (61 %) followed by gastroduodenal erosions (15.4 %) and varicous veins (5.7 %). Indications for emergency surgery were massive UGIB or rebleeding after active endoscopic treatment. On operation, gastric and duodenal ulcers were responsible for massive UGIB in 86.4 % cases. Overall hospital mortality rate during 10 years was 13.2 % and depended on age and concomitant diseases. In total 5.9 % of operated patients were rebleeding. Those with rebleeding underwent a second operation and showed a statistically higher mortality rate (35.7 % vs 11.8 %) compared to those surgical patients without rebleeding; p < 0.001. The mortality rate after vagotomy and pyloroplasty was 13.2 % (14/106) and did not differ significantly from that after gastric resection (15.2 %; 9/59).     

Relative hypotension increases the probability of the need for angioembolisation in pelvic fracture patients without contrast extravasation on computed tomography scan

IntroductionIn the evaluation of haemorrhage in trauma patients with pelvic fractures, contrast extravasation (CE) on computed tomography (CT) scan often implies active arterial bleeding. However, the absence of CE on CT scan does not always exclude the need for transcatheter arterial embolisation (TAE) to achieve haemostasis. In the current study, we evaluated the factors associated with the need for TAE in patients without CE on CT scan. These factors may be evaluated as adjuncts to CT scanning in the management of patients with pelvic fractures.MethodsWe retrospectively reviewed our trauma registry and medical records of patients with pelvic fractures. When CE was observed, indicating active haemorrhage, the patients underwent TAE to achieve haemostasis. In contrast, patients without CE were held for observation and treatment of their injuries, and if their condition deteriorated after a delayed interval, they were then also referred for TAE if no other focus of haemorrhage was found. Patients without CE on CT scan but with retroperitoneal haemorrhage requiring TAE were investigated. Their demographic characteristics, associated injuries, fracture patterns, and changes in systolic blood pressure were described and analysed.ResultsIn total, 201 patients with pelvic fracture underwent CT scan examination; 47 (23.4%) had CE by CT scan, whereas the other 154 (76.6%) did not. Of the 154 patients who did not show CE by CT scan, 124 (80.5%) patients never underwent TAE; however, 30 (19.5%) of these patients did eventually undergo TAE. In comparing the patients who underwent TAE to those who did not undergo TAE among patients without CE on CT scan, the systolic blood pressure (SBP) on arrival (median: 100.0 mmHg vs 136.0 mmHg, p < 0.01) and the lowest SBP recorded in the ED (median: 68.0 mmHg vs 129.0 mmHg, p < 0.01) were significantly lower in the patients who underwent TAE. The ROC curve analysis revealed that the most appropriate cutoff value of decrement of SBP (SBP on arrival minus the lowest SBP in the ED) was 30 mmHg (AUC = 0.89).ConclusionIn the management of pelvic fracture patients, greater attention should be directed toward patients with relative hypotension. The higher likelihood of haemodynamic deterioration and the need for TAE for haemorrhage control should remain under consideration in such cases, despite the absence of CE by CT scan.     

Survival after transarterial embolization for spontaneous ruptured hepatocellular carcinoma

Objectives  To examine the survival of patients with spontaneous ruptured hepatocellular carcinoma treated with transarterial embolization (TAE). Methods and materials  Patients diagnosed with spontaneous ruptured hepatocellular carcinoma treated with TAE were retrospectively studied. Hospital records were reviewed and data were collected and analyzed from the years 2000–2006. A total of 62 patients who had been diagnosed with spontaneous ruptured hepatocellular carcinoma were managed in our hospital during this period. Results  All 62 patients (who had been diagnosed with ruptured hepatocellular carcinoma and were managed in our hospital) patients were treated with TAE, with a success rate of 91% (57/62). Early mortality (within 30 days after rupture) was 38%. Factors that were associated with early mortality were old age, low hemoglobin at presentation, elevated bilirubin at presentation, prolonged prothrombin time at presentation (INR > 1.3), low albumin level at presentation, and unsuccessful embolization. A low albumin level was the only independent risk factor for early mortality. The overall median survival time was 39 days. Surgical resections were possible in seven patients. Their cumulative survival was significantly longer (P = 0.002) than that of patients managed with non-operative treatment after embolization. Conclusion  Transarterial embolization (TAE) can achieve good hemostasis, though low albumin level, which reflects poor liver reserve, may predict early mortality. Portal vein thrombosis should not be regarded as an absolute contraindication for TAE. Staged surgical resection after embolization is safe and produces a good survival outcome.     

Preinjury warfarin does not cause failure of nonoperative management in patients with blunt hepatic,splenic or renal injuries

BackgroundFor patients sustaining major trauma, preinjury warfarin use may make adequate haemostasis difficult. This study aimed to determine whether preinjury warfarin would result in more haemostatic interventions (transarterial embolization [TAE] or surgeries) and a higher failure rate of nonoperative management for blunt hepatic, splenic or renal injuries.MethodsThis was a retrospective cohort study from the Taiwan National Health Insurance Research Database (NHIRD) from 2003 to 2015. Patients with hepatic, splenic or renal injuries were identified. The primary outcome measurement was the need for invasive procedures to stop bleeding. One-to-two propensity score matching (PSM) was used to minimize selection bias.ResultsA total of 37,837 patients were enrolled in the study, and 156 (0.41%) had preinjury warfarin use. With proper 1:2 PSM, patients who received warfarin preinjury were found to require more haemostatic interventions (39.9% vs. 29.1%, p=0.016). The differences between the two study groups were that patients with preinjury warfarin required more TAE than the controls (16.3% vs 8.2%, p = 0.009). No significant increases were found in the need for surgeries (exploratory laparotomy (5.2% vs 3.6%, p = 0.380), hepatorrhaphy (9.2% vs 7.2%, p = 0.447), splenectomy (13.1% vs 13.7%, p = 0.846) or nephrectomy (2.0% vs 0.7%, p = 0.229)). Seven out of 25 patients (28.0%) in the warfarin group required further operations after TAE, which was not significantly different from that in the nonwarfarin group (four out of 25 patients, 16.0%, p = 0.306)ConclusionPreinjury warfarin increases the need for TAE but not surgeries. With proper haemostasis with TAE and resuscitation, nonoperative management can still be applied to patients with preinjury warfarin sustaining blunt hepatic, splenic or renal injuries. Patients with preinjury warfarin had a higher risk for surgery after TAE.     

IMPACT-Global Hip Fracture Audit: Nosocomial infection,risk prediction and prognostication,minimum reporting standards and global collaborative audit: Lessons from an international multicentre study of 7,090 patients conducted in 14 nations during the COVID-19 pandemic

AimsThis international study aimed to assess: 1) the prevalence of preoperative and postoperative COVID-19 among patients with hip fracture, 2) the effect on 30-day mortality, and 3) clinical factors associated with the infection and with mortality in COVID-19-positive patients.MethodsA multicentre collaboration among 112 centres in 14 countries collected data on all patients presenting with a hip fracture between 1st March-31st May 2020. Demographics, residence, place of injury, presentation blood tests, Nottingham Hip Fracture Score, time to surgery, management, ASA grade, length of stay, COVID-19 and 30-day mortality status were recorded.ResultsA total of 7090 patients were included, with a mean age of 82.2 (range 50–104) years and 4959 (69.9%) being female. Of 651 (9.2%) patients diagnosed with COVID-19, 225 (34.6%) were positive at presentation and 426 (65.4%) were positive postoperatively. Positive COVID-19 status was independently associated with male sex (odds ratio (OR) 1.38, p = 0.001), residential care (OR 2.15, p < 0.001), inpatient fall (OR 2.23, p = 0.003), cancer (OR 0.63, p = 0.009), ASA grades 4 (OR 1.59, p = 0.008) or 5 (OR 8.28, p < 0.001), and longer admission (OR 1.06 for each increasing day, p < 0.001). Patients with COVID-19 at any time had a significantly lower chance of 30-day survival versus those without COVID-19 (72.7% versus 92.6%, p < 0.001). COVID-19 was independently associated with an increased 30-day mortality risk (hazard ratio (HR) 2.83, p < 0.001). Increasing age (HR 1.03, p = 0.028), male sex (HR 2.35, p < 0.001), renal disease (HR 1.53, p = 0.017), and pulmonary disease (HR 1.45, p = 0.039) were independently associated with a higher 30-day mortality risk in patients with COVID-19 when adjusting for confounders.ConclusionThe prevalence of COVID-19 in hip fracture patients during the first wave of the pandemic was 9%, and was independently associated with a three-fold increased 30-day mortality risk. Among COVID-19-positive patients, those who were older, male, with renal or pulmonary disease had a significantly higher 30-day mortality risk.     

经导管动脉栓塞术治疗重症急性胰腺炎并发假性动脉瘤破裂出血

目的探讨经导管动脉栓塞术(TAE)在重症急性胰腺炎(SAP)并发假性动脉瘤破裂出血中的应用价值。方法对13例SAP并发假性动脉瘤破裂出血患者行TAE,分析假性动脉瘤DSA表现及栓塞情况。结果 13例SAP患者共并发15个假性动脉瘤,包括感染性假性动脉瘤13个、腐蚀性假性动脉瘤2个。6个(6/15,40.00%)假性动脉瘤的责任动脉为脾动脉,5个(5/15,33.33%)为肠系膜上动脉,2个(2/15,13.33%)为胃十二指肠动脉,1个(1/15,6.67%)为肠系膜下动脉,1个(1/15,6.67%)为胃网膜右动脉(1/15,6.67%)。TAE治疗技术成功率为93.33%(14/15)。1例(1个假性动脉瘤)TAE术后出现脾脓肿,经穿刺引流及抗感染好转。感染性假性动脉瘤患者死亡率为45.45%(5/11),腐蚀性假性动脉瘤无死亡患者。TAE术后复发出血率为15.38%(2/13)。结论 TAE是治疗SAP并发假性动脉瘤破裂出血的有效方法。     

Preoperative hyponatremia is associated with postoperative major morbidity,prolonged length of stay,non-home discharge,and readmission in total shoulder arthroplasty

IntroductionHyponatremia is a known risk factor for postoperative complications, but prior research has not investigated its outcomes in patients undergoing total shoulder arthroplasty (TSA). The purpose of this study was to determine the association between preoperative hyponatremia and postoperative 30-day major morbidity, 30-day reoperation, length of stay (LOS), non-home discharge, and 30-day readmission.MethodsPatients undergoing anatomic or reverse TSA from 2012 to 2016 were identified in the American College of Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP) database. A multiple logistic regression model was estimated for associated outcomes. An alpha level of 0.005 was used after accounting for Bonferroni correction.ResultsPrimary analysis of 12,437 patients showed significant independent association of preoperative hyponatremia with 30-day major morbidity (OR = 2.00; 99% CI: 1.46–2.73), LOS greater than the 75th percentile (OR = 1.63; 99% CI: 1.31–2.03), non-home discharge (OR = 1.73; 99% CI: 1.08–2.79), and 30-day readmission (OR = 1.69; 99% CI: 1.08–2.64), but not with 30-day reoperation (OR = 1.55; 99% CI: 0.75–3.19).ConclusionPreoperative hyponatremia in TSA was significantly associated with increased odds of 30-day postoperative major morbidity, prolonged LOS, non-home discharge, and 30-day readmission compared to preoperative normonatremia. These findings emphasize the importance of pre-admission testing prior to undergoing elective orthopedic procedures. Additional research is needed to stratify hyponatremia by severity and measure the impact of correcting hyponatremia in patients planning on undergoing TSA.Level of EvidenceLevel III; Retrospective Study-Defined     

Thoracic endovascular aortic repair with stent grafts alone or with a composite device design in patients with acute type B aortic dissection in the setting of malperfusion

ObjectiveThe objective of this study was to compare short-term outcomes in patients who underwent thoracic endovascular aortic repair (TEVAR) with stent grafts alone or with a composite device design (stent graft plus bare-metal aortic stent) for acute type B aortic dissection in the setting of malperfusion.MethodsThis retrospective analysis included patients with acute (≤14 days of symptom onset) complicated type B dissection in the setting of malperfusion who were treated with stent grafts alone (TEVAR cohort) at two European institutions vs those who underwent TEVAR with a composite device design (Cook Medical, Bloomington, Ind) in the investigational STABLE I feasibility study and STABLE II pivotal study (STABLE cohort). Preoperative characteristics and 30-day outcomes (including mortality, malperfusion-related mortality, morbidity, and secondary interventions) were compared between the two groups.ResultsThe TEVAR cohort (41 patients; mean age, 58.8 ± 12.7 years; 78.0% male) and the STABLE cohort (84 patients; mean age, 57.8 ± 11.7 years; 71.4% male) were largely similar in preoperative medical characteristics, with more STABLE patients presenting with a history of hypertension (79.8% vs 58.5%; P = .018). The TEVAR and STABLE groups had similar lengths of dissection (451.8 ± 112.7 mm vs 411.8 ± 116.4 mm; P = .10) and similar proximal and distal extent of dissection. At presentation, the two groups exhibited comparable organ system involvement in malperfusion: renal (53.7% TEVAR, 57.1% STABLE), gastrointestinal (41.5% TEVAR, 44.0% STABLE), lower extremities (34.1% TEVAR, 52.4% STABLE), and spinal cord (9.8% TEVAR, 2.4% STABLE). The 30-day rate of all-cause mortality was 17.1% (7/41) in the TEVAR group and 8.3% (7/84) in the STABLE group (P = .22). The 30-day rate of malperfusion-related mortality (deaths from bowel/mesenteric ischemia or multiple organ failure) was 12% (5/41) in the TEVAR group and 2.4% (2/84) in the STABLE group (P = .038). The 30-day morbidity, for the TEVAR and STABLE groups, respectively, included bowel ischemia (9.8% [4/41] vs 2.4% [2/84]; P = .09), renal failure requiring dialysis (7.3% [3/41] vs 9.5% [8/84]; P > .99), paraplegia or paraparesis (4.9% [2/41] vs 3.6% [3/84]; P = .66), and stroke (2.4% [1/41] vs 10.7% [9/84]; P = .16). The occurrence of 30-day secondary intervention was similar in the TEVAR and STABLE groups (7.3% [3/41] vs 7.1% [6/84]; P > .99). True lumen expansion in the abdominal aorta was significantly greater in the STABLE group.ConclusionsIn patients with acute type B aortic dissection in the setting of branch vessel malperfusion, the use of a composite device with proximal stent grafts and distal bare aortic stent appeared to result in lower malperfusion-related mortality than the use of stent grafts alone. The 30-day rates of morbidity and secondary interventions were similar between the groups.     

Major National Shifts to Outpatient Total Knee Arthroplasties in the United States: A 10-Year Trends Analysis of Procedure Volumes,Complications, and Healthcare Utilizations (2010 to 2020)

BackgroundThe removal of total knee arthroplasty (TKA) from inpatient-only lists accelerated changes in orthopaedic surgical practices across the United States. This study aimed to (1) quantify the annual volume of inpatient/outpatient primary TKAs; (2) compare patient characteristics before/after the year 2018; and (3) compare annual trends in 30-day readmissions, 30-day complications, and healthcare utilization parameters for inpatient/outpatient TKAs.MethodsThe National Surgical Quality Improvement Program was reviewed (January 2010 to December 2020) for patients who underwent primary TKA (n = 470,456). The primary outcome was annual volumes of inpatient/outpatient TKA. Secondary outcomes included 30-day readmissions, 30-day reoperations, and 30-day major/minor complications. Demographic characteristics and healthcare utilization parameters (hospital lengths of stay and discharge dispositions) were compared between cohorts via Chi-square goodness-of-fit tests.ResultsOverall, 89% had inpatient TKA (n = 416,972) and 11% had outpatient TKA (n = 53,854). Between 2017 and 2020, annual volumes of outpatient TKA increased by 1,925 (1,019 to 20,633), while inpatient TKA decreased by 53% (61,874 to 29,280). Patients who had outpatient TKA after 2018 were older (P < .001), predominantly males (P < .001), more commonly White (P < .001), and had a greater proportion of American Society of Anesthesiologists class III (P < .001). The inpatient cohort had higher rates of 30-day readmissions, reoperations, and complications. Average length of stay and nonhome discharges decreased for both cohorts.ConclusionOutpatient TKA increased 20-fold at NSQIP hospitals. The changes in comorbidity profiles and the increase in volumes of outpatient TKA were not associated with a rise in cumulative 30-day readmissions and complications. Further research and policy endeavors should focus on identifying patients who still require or benefit from inpatient TKA.     

Impact of suprarenal neck angulation on endovascular aneurysm repair outcomes

BackgroundHostile infrarenal proximal neck (β) anatomy of abdominal aortic aneurysm has been associated with increased risk of aneurysm-related complications after endovascular aneurysm repair (EVAR). However, there is a paucity of literature addressing the suprarenal angle (α). The aim of this study was to evaluate short- and long-term outcomes after EVAR in patients with severe suprarenal neck angulation (α >60 degrees).MethodsA retrospective review of the medical records of 561 patients who underwent EVAR between January 2005 and December 2017 was performed. The main exclusion criteria were preoperative aneurysm rupture and fenestrated or branched endograft placement. High-resolution computed tomography images of 452 patients were available. Patients were grouped into angulated (α >60 degrees) and nonangulated (α ≤60 degrees) groups. The primary end point was freedom from type IA endoleak. Secondary end points included 30-day mortality, long-term survival, primary clinical success, and freedom from aneurysm rupture and graft migration. Primary clinical success was defined according to Society for Vascular Surgery guidelines as clinical success without the need for an additional or secondary surgical or endovascular procedure.ResultsOf 452 patients, 45 (10%) were included in the angulated group (α >60 degrees). Median follow-up time was 34 months (interquartile range, 14-56 months). Compared with patients in the nonangulated group, those in the angulated group had larger neck diameter at the level of the renal arteries (mean [standard deviation], 25.6 [3.8] mm vs 24.6 [3.4] mm; P = .06) and increased β angle (mean [standard deviation], 50.5 [22.9] degrees vs 41.6 [23.9] degrees; P = .01). The 3-year freedom from type IA endoleak estimate was 80.2% for the angulated group compared with 97.8% for the nonangulated group (P < .001). The angulated group showed significantly higher 30-day mortality (11.1% vs 0.25%; P < .001).The 3-year results showed that patients in the nonangulated group had higher rates of primary clinical success (90.2% vs 67.1%; P < .001), freedom from rupture (99% vs 97.1%; P = .02), freedom from migration (100% vs 92.4%; P < .001), and long-term survival (91.6% vs 75.8%; P = .006) compared with those in the angulated group. After adjustment for age, sex, neck diameter, and β angle, severe suprarenal neck angulation was associated with higher odds of type IA endoleak (adjusted hazard ratio, 8.9; 95% confidence interval [CI], 2.9-27), loss of primary clinical success (adjusted hazard ratio, 4.8; 95% CI, 2.6-8.9), and 30-day mortality (adjusted odds ratio, 52.5; 95% CI, 5.3-514) compared with α ≤60 degrees (all P < .001).ConclusionsThis is the first report to show a significant increase in operative mortality in patients undergoing EVAR with severely angulated suprarenal neck. Patients who survive the operation are at increased risk of secondary interventions. These findings suggest that EVAR should be used with caution in patients with severe α angulation and underpin the role of close follow-up in this particular population.     

Immediate and 1-year success rate of type 2 endoleak treatment using three-dimensional image fusion guidance

PurposeTo retrospectively assess immediate and 1-year success rate of type 2 endoleak (T2E) treatment with ethylene-vinyl-alcohol-polymer using three-dimensional (3D) image fusion guidance with cone beam computed tomography via trans-arterial embolization (TAE) or direct percutaneous sac injection (DPSI).Materials and methodsA total of 37 patients with T2E who were treated either using TAE (34/37; 92%) or DPSI (9/37; 8%) were included. There were 34 men and 3 women with a mean age of 86 ± 9 (SD) years (range: 67–104 years). Mean aneurysm diameter was 67 ± 14 (SD) mm (range: 42–101 mm) at pre-procedure evaluation. Immediate success was complete embolization of the sac and feeding artery. 1-year success was reduction or stability of the aneurysmal sac diameter based on pre-procedure and 12-month follow-up examinations. Safety (treatment-related complications), patient demographics, duration of procedure and contrast volume were reported.ResultsImmediate and 1-year successful outcomes were reported in 94% (n = 32) and 88% (n = 28) of patients after TAE and 100% (n = 9) and 89% (n = 8) after DPSI. T2E treatments were immediately successful for 95% of the procedures (41/43) and for 88% (36/41) at 1 year. Overall, T2E treatment was effective in 33 patients (89%). No major complications occurred. Mean procedure time and contrast volume were significantly different between the 2 techniques with respectively 87 ± 16 (SD) min (range: 65–120 min) and 75 ± 26 (SD) mL (range: 40–130 mL) for TAE and 32 ± 10 (SD) min (range: 20–50 min) (P < 0.01) and 6 ± 6 (SD) mL (range: 2–22 mL) (P < 0.01) for DPSI. Mean aneurysm diameter at 1-year was 68 ± 17 (SD) mm (range: 43–101 mm). No significant differences in the pre-procedure sac diameter were found at long-term follow-up between patients without T2E and those with persistent T2E (P = 0.1) in the successful embolization group (n = 33).ConclusionTAE or DPSI treatments of T2E with ethylene-vinyl-alcohol-polymer using 3D-image fusion guidance were immediately successful for 95% of the procedures and remained effective for 88%. Longer follow-up is necessary to assess sac stability in the case of persistent endoleak.     

Glubran-2胶经导管动脉栓塞治疗经皮肝穿刺胆道引流术后出血

目的 观察以Glubran-2胶经导管动脉栓塞(TAE)治疗经皮肝穿刺胆道引流术(PTCD)后出血的效果。方法 回顾性分析17例接受Glubran-2胶TAE治疗PTCD后出血的患者,观察技术成功率、临床成功率及并发症情况;比较TAE后当日与次日红细胞(RBC)及血红蛋白(Hb)差异;比较TAE前与TAE次日及第2日、TAE前与TAE后第4日谷丙转氨酶(GPT)差异。结果 17例均经TAE成功栓塞责任血管,技术成功率及临床成功率均为100%;均未出现肝脓肿、败血症及肺栓塞等严重并发症。TAE后当日与次日,RBC及Hb差异均无统计学意义(P均>0.05);TAE前GPT低于TAE后次日及第2日(P<0.05),TAE前与TAE后第4日GPT差异无统计学意义(P>0.05)。结论 以Glubran-2胶行TAE治疗PTCD后出血安全、有效。     

Outcome After 7 Years of Carotid Artery Stenting and Endarterectomy in Sweden – Single Centre and National Results

ObjectivesThe aim was internal vascular centre quality-control measures to compare single-centre results with the national perspective, as well as analysing the Swedish results from carotid artery stenting (CAS) and comparing a relatively high-volume single centre with the Swedish Vascular Registry (Swedvasc) data. The second aim was to compare CAS and carotid artery endarterectomy (CEA) outcomes for the same 7-year period.DesignRetrospective review of a single high-volume centre (Södersjukhuset (SÖS)) (approximately 30 CAS year^?1 approximately 90 CEA year^?1) versus Swedvasc National data.Materials and methodsAll consecutive selective patients treated with CAS at SÖS for a stenosis of the internal carotid artery (n = 208) or CEA (n = 552) between 2004 and 2011 were compared with all patients in Swedvasc registered for CAS (n = 258) and CEA (n = 6474). Primary outcome was 30-day frequency of stroke or death. Secondary outcome was stroke/death/acute myocardial infarction (AMI).ResultsThe 30-day frequency of any stroke or death after CAS at SÖS compared to the national data was 2.9% and 7.4%, respectively (P = 0.04). The 30-day AMI/stroke/death frequency was 3.4% and 9.5%, respectively (P = 0.01). After CEA during the same time period, the Swedvasc national data had a 4.4% frequency of 30-day stroke and death and 5.8% for AMI/stroke/death.ConclusionsCAS is not as safe as CEA from a national perspective but our results indicate that a single centre can achieve acceptable results with CAS.     

Updated outcomes from the TRANSFIX study to evaluate endovascular repair of blunt thoracic aortic injuries with the Zenith Alpha thoracic device

ObjectiveThe purpose of this study was to report the updated results of a prospective, multicenter, nonrandomized, single-arm investigational device exemption study conducted at 17 sites in the United States to assess safety and effectiveness of the Zenith Alpha thoracic endovascular graft (Cook Medical, Bloomington, Ind) for treatment of blunt thoracic aortic injury (BTAI).MethodsThe primary safety end point was 30-day all-cause mortality and aortic injury-related mortality. The primary effectiveness end point was 30-day device success. Additional outcomes evaluated included major adverse events and imaging findings including aortic injury healing, graft patency, and device integrity as analyzed by the core laboratory on follow-up computed tomography imaging through 5 years.ResultsA total of 50 patients with BTAI were enrolled in the TRANSFIX study between January 2013 and May 2014. Mean follow-up was 21 months (range, 0.6-35 months). The 30-day mortality was 2% (n = 1), and it was unrelated to the aortic repair or study device. Five deaths occurred after 30 days, and one was considered procedure related. Freedom from all-cause and BTAI-related mortality was 89.3% and 97.6%, respectively, at 2 years. Aortic injury healing was noted in 96% at 2 years. An incidental finding of thrombus formation within the stent graft, most commonly at the distal aspect of the study device, occurred in 15 patients (30%; 12 by core laboratory, 3 by site) and was confirmed in 13 patients (26%). None of these patients were noted to have clinical sequelae on most recent follow-up.ConclusionsThe updated results from the TRANSFIX study continue to show low rates of aortic injury-related mortality and major adverse events during follow-up. However, findings of in-graft thrombus have resulted in the manufacturer's voluntary removal of the BTAI indication for this device. Caution should be exercised in appropriate and accurate device sizing and planning (eg, limiting graft oversizing) as well as in regular, lifelong follow-up evaluation.